Feb. 14, 2007 — Vital Signs Inc.’s Swedish sister company, Breas Medical AB, has received FDA clearance to market a new continuous positive airway pressure (CPAP) device, the iSleep 20i.
A high performance, advanced version of a previously cleared Breas CPAP device, iSleep 20i incorporates an enhanced "i-technology" detection algorithm that responds to subtle changes in the patient's breathing patterns, before significant apnea events can occur.
Vital Signs says the technology is based on breathing pattern recognition by a neural network. The treatment can be effective at a reduced mean pressure level compared to conventional CPAP devices — the pressure required by the patient normally varies during sleep and is adjusted accordingly. Most patients prefer lower treatment pressures.
In addition, Vital Signs has signed a letter of intent to acquire Sleep Services of America (SSA), which performs approximately 3,000 sleep studies per year. It is the third company Vital Signs is targeting for possible purchase.
For more information, visit www.vital-signs.com